Dihydropyrrolopyrazole Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors: A Novel Benzimidazole Series with Selectivity versus Transforming Growth Factor-β Type II Receptor Kinase and Mixed Lineage Kinase-7
- 21 February 2006
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (6) , 2138-2142
- https://doi.org/10.1021/jm058209g
Abstract
Novel dihydropyrrolopyrazole-substituted benzimidazoles were synthesized and evaluated in vitro as inhibitors of transforming growth factor-beta type I receptor (TGF-beta RI), TGF-beta RII, and mixed lineage kinase-7 (MLK-7). These compounds were found to be potent TGF-beta RI inhibitors and selective versus TGF-beta RII and MLK-7 kinases. Benzimidazole derivative 8b was active in an in vivo target (TGF-beta RI) inhibition assay.Keywords
This publication has 15 references indexed in Scilit:
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004
- Inhibition of Transforming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542Molecular Pharmacology, 2002
- SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7Molecular Pharmacology, 2002
- Identification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type 1 Receptor (ALK5)Journal of Medicinal Chemistry, 2002
- Smad regulation in TGF-β signal transductionJournal of Cell Science, 2001
- TGF- β signaling in cancer – a double-edged swordTrends in Cell Biology, 2001
- The TGFβ Receptor Activation ProcessMolecular Cell, 2001
- TGFβ Signaling in Growth Control, Cancer, and Heritable DisordersCell, 2000
- Role of Transforming Growth Factor-beta Signaling in CancerJNCI Journal of the National Cancer Institute, 2000
- Transforming growth factor β signaling mediators and modulatorsGene, 2000